The Saudi Arabian influenza vaccine market was valued at USD 76.15 million in 2022 and is projected to reach USD 140.22 million by 2030, growing at a compound annual growth rate (CAGR) of 7.93% between 2023 and 2030. Several key factors contributing to market growth include heightened awareness of the disease’s severity, physician recommendations, past experiences with influenza, improvements in pharmaceutical infrastructure, confidence in vaccine efficacy, and adherence to both local and international health guidelines.
Recognizing the critical role of influenza vaccination in reducing virus transmission and easing the burden on the healthcare system, the Saudi government has made vaccination campaigns a national priority. This commitment reflects the country’s dedication to public health and preventive care, helping to drive market growth.
Additionally, the rising incidence of influenza cases and seasonal outbreaks has increased demand for vaccines. Like other nations, Saudi Arabia experiences significant influenza activity during flu seasons, reinforcing the need for immunization to curb the virus’s spread. The market has also benefited from advancements in vaccine technology and the availability of more options, particularly quadrivalent vaccines, which protect against four strains of influenza and have gained popularity for their enhanced effectiveness.
Click – https://www.marketsandata.com/industry-reports/saudi-arabia-influenza-vaccine-market
Rising Influenza Burden
According to the World Health Organization (WHO), influenza surveillance data show a marked increase in cases. Positive influenza cases, influenza-like illnesses (ILIs), and severe acute respiratory infections (SARIs) have surged. Specifically, positive cases rose from 3.75% to 25.11%, ILIs increased from 45 to 344, and SARIs escalated from 82 to 303 between 2021 and 2022.
In response, the Saudi Ministry of Health (MOH) has urged residents to visit primary healthcare centers for seasonal influenza vaccines (SIV), citing a significant rise in influenza and ILI cases in 2022. This increase has put additional pressure on the country’s healthcare system, reinforcing the demand for influenza vaccines.
Expansion of Pharmaceutical Infrastructure
Saudi Arabia is making major investments in its pharmaceutical sector to enhance vaccine availability and administration. Recognizing the importance of proactive healthcare measures, the country is strengthening pharmaceutical education, research, and manufacturing capabilities. Universities and research centers are forming partnerships with international organizations to advance pharmaceutical studies, research, and innovation.
A notable example is the launch of Lifera, a Contract Development and Manufacturing Organization (CDMO) established by Saudi Arabia’s Public Investment Fund (PIF) in June 2023. Lifera aims to boost domestic biopharmaceutical production, with a focus on insulin, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules. This initiative underscores Saudi Arabia’s commitment to developing its local pharmaceutical industry.
Government Initiatives
To promote flu vaccinations, Saudi Arabia’s MOH launched a 2021 awareness campaign targeting high-risk groups, including the elderly, individuals with chronic conditions, immunocompromised patients, pregnant women, healthcare workers, and the general public.
In 2022, the country introduced the Integrated Influenza Sentinel Surveillance System (IISS), its most advanced influenza monitoring system to date. This system comprises a network of 100 sites, including 30 hospitals and 70 primary healthcare clinics, integrating on-site molecular testing for influenza, respiratory syncytial virus (RSV), and rapid COVID-19 testing. The IISS also facilitates genomic sequencing to track virus transmission patterns and identify emerging variants.
Advancements in Recombinant Vaccines
Recombinant subunit vaccines address challenges related to traditional vaccine production, such as the use of chicken embryos and the need to weaken pathogenic strains. These vaccines utilize expression systems to rapidly produce targeted viral proteins, offering an alternative approach to conventional methods.
For instance, Flublok, developed by Sanofi Pasteur, is a recombinant flu vaccine produced using baculoviral vectors in insect cell lines. This method allows for the efficient production of influenza antigens, contributing to innovation in vaccine development.
Growing Demand for Quadrivalent Flu Vaccines
The rising demand for quadrivalent influenza vaccines is significantly impacting the Saudi market. Unlike trivalent vaccines, which protect against three flu strains, quadrivalent vaccines cover an additional B strain, offering broader protection.
An example of this is Flulaval QIV, developed by GlaxoSmithKline (GSK), which is designed to immunize individuals aged three years and older against influenza A and B virus subtypes. The increasing preference for quadrivalent vaccines is expected to drive further market expansion.
Impact of COVID-19
Before the COVID-19 pandemic, influenza vaccination rates in Saudi Arabia stood at approximately 37.1% for individuals aged 65 and older and around 45% among the general population. By 2021, vaccine uptake increased to 45% in northern Saudi Arabia due to simultaneous COVID-19 and flu vaccination campaigns.
However, adherence to general preventive measures declined post-pandemic, contributing to a rise in influenza-like illnesses and severe acute respiratory infections in 2022. Vaccine hesitancy, particularly regarding the seasonal flu vaccine, also became a factor, affecting overall immunization rates.
Saudi Arabia Influenza Vaccine Market Outlook (2023-2030)
- Increasing income levels and urbanization are expected to drive market growth.
- The Saudi government is enforcing stricter emission control regulations, encouraging a shift toward sustainable healthcare measures such as influenza vaccination.
- Higher fuel prices, government-backed healthcare initiatives, and expansion of vaccine manufacturers in the country are fostering market growth.
- A growing portion of the population is prioritizing preventive healthcare, increasing demand for influenza vaccines.
Market Scope
The report “Saudi Arabia Influenza Vaccine Market Assessment, Opportunities, and Forecast, 2016-2030” provides an in-depth analysis of market trends, industry dynamics, and challenges. It includes market size, segmental shares, growth forecasts, the impact of COVID-19, and future opportunities. Additionally, it highlights key industry players, their market share, business strategies, and competitive landscape.
Contact
Mr. Vivek Gupta5741 Cleveland street,Suite 120, VA beach, VA, USA 23462Tel: +1 (757) 343–3258Email: info@marketsandata.comWebsite: https://www.marketsandata.com
